Royal Bank of Canada Reiterates “€130.00” Price Target for MorphoSys (ETR:MOR)
Royal Bank of Canada set a €130.00 ($151.16) target price on MorphoSys (ETR:MOR) in a report issued on Friday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
A number of other brokerages also recently issued reports on MOR. Berenberg Bank set a €150.00 ($174.42) price target on shares of MorphoSys and gave the company a buy rating in a report on Monday, August 5th. Independent Research set a €96.00 ($111.63) price target on shares of MorphoSys and gave the company a neutral rating in a report on Thursday, July 4th. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the company a neutral rating in a report on Wednesday, August 7th. Deutsche Bank set a €133.00 ($154.65) price target on shares of MorphoSys and gave the company a buy rating in a report on Thursday. Finally, JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of MorphoSys and gave the company a buy rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of €113.56 ($132.04).
Shares of ETR MOR opened at €111.00 ($129.07) on Friday. The company’s 50-day moving average is €96.61. The company has a debt-to-equity ratio of 8.61, a quick ratio of 7.40 and a current ratio of 7.62. The stock has a market cap of $3.50 billion and a P/E ratio of -84.03. MorphoSys has a 52-week low of €76.45 ($88.90) and a 52-week high of €114.60 ($133.26).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.